Cargando…
Cardiorenal and endocrine effects of synthetic canine BNP1‐32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease
BACKGROUND: The effects of synthetic brain natriuretic peptide (BNP1‐32) on cardiorenal and renin angiotensin aldosterone system in dogs with naturally occurring congestive heart failure (CHF) are unknown. OBJECTIVES: To evaluate the cardiorenal and endocrine effects of SC administered synthetic can...
Autores principales: | Yata, Mariko, Kooistra, Hans S., Beijerink, Niek J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430907/ https://www.ncbi.nlm.nih.gov/pubmed/30703246 http://dx.doi.org/10.1111/jvim.15416 |
Ejemplares similares
-
Effect of prespecified therapy escalation on plasma NT‐proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease
por: Hezzell, Melanie J., et al.
Publicado: (2018) -
Radiographic lung congestion scores in dogs with acute congestive heart failure caused by myxomatous mitral valve disease
por: Koster, Liza, et al.
Publicado: (2023) -
Atrial Fibrillation as a Prognostic Indicator in Medium to Large‐Sized Dogs with Myxomatous Mitral Valvular Degeneration and Congestive Heart Failure
por: Jung, S.W., et al.
Publicado: (2016) -
Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST)
por: Coffman, Melissa, et al.
Publicado: (2021) -
The Mitral INsufficiency Echocardiographic score: A severity classification of myxomatous mitral valve disease in dogs
por: Vezzosi, Tommaso, et al.
Publicado: (2021)